The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Jun. 20, 2017

Filed:

May. 10, 2011
Applicants:

Mark E. Westerman, San Diego, CA (US);

Rinaldo Bellomo, Ivanhoe, AU;

John Prowle, London, GB;

Michael Brownstein, Rockville, MD (US);

Inventors:

Mark E. Westerman, San Diego, CA (US);

Rinaldo Bellomo, Ivanhoe, AU;

John Prowle, London, GB;

Michael Brownstein, Rockville, MD (US);

Assignees:

INTRINSIC LIFESCIENCES LLC, LaJolla, CA (US);

AUSTIN HEALTH, Victoria, AU;

Attorney:
Primary Examiner:
Int. Cl.
CPC ...
G01N 33/70 (2006.01); G01N 33/68 (2006.01); G01N 33/74 (2006.01);
U.S. Cl.
CPC ...
G01N 33/70 (2013.01); G01N 33/6893 (2013.01); G01N 33/74 (2013.01); G01N 2333/705 (2013.01); G01N 2800/347 (2013.01); G01N 2800/60 (2013.01);
Abstract

Provided are methods and compositions for predicting the development of kidney disease, including acute kidney injury. In certain aspects and embodiments the provided methods and compositions are particularly useful for predicting kidney injury following an event likely to cause kidney injury and/or kidney failure in a patient, such as a cardiac surgery, e.g., a surgery involving a cardiopulmonary bypass (CPB), such as a coronary artery bypass graft surgery. In some embodiments, the higher the urinary hepcidin-to-urinary creatinine ratio (uHep/uCr) at 6-24 hours following initiation of CPB, the lower is the risk for development of AKI determined by RIFLE criteria in the ensuing four to five days. Conversely, the higher the urinary NGAL to urinary creatinine ratio (uNGAL/uCr) at 6-24 hours following initiation of CPB, the higher is the risk of developing CPB-mediated AKI over the same time period.


Find Patent Forward Citations

Loading…